Jasper Hikes on Cell Development




Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares sprang Monday, as the Redwood City, Calif.-based company, a clinical stage biotechnology concern focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.

“Mast cells are critical drivers of the inflammatory response in asthma,” said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine. “These cells are located in multiple compartments in the lungs and, when triggered, release potent mediators such as histamine, cytokines, tryptase and others that contribute to the asthmatic response. At the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting in February we presented preclinical data generated in our c-Kit Mouse™ demonstrating that briquilimab led to the depletion of mast cells in the airways and prevented an allergen-induced asthmatic response. We look forward to reviewing these preclinical data at our KOL webinar next week and at upcoming conferences.”

The Company will host a KOL webinar on the potential of briquilimab in asthma next Monday. Its shares kicked off Monday up 64 cents, or 3%, to $21.97.



Source link

About The Author

Scroll to Top